SCHEMBL4335296

SCHEMBL4335296

O=C(Nc1ccc(CCl)cc1)c1ccccc1C(=O)Nc1ccc(CCl)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.63
ALDH1A1 P00352 3/20 0.56
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MEN1 O00255 2/20 0.55
TDP1 Q9NUW8 1/20 0.55
FFAR1 O14842 1/20 0.54
KLKB1 P03952 1/20 0.54
SMO Q99835 3/20 0.54
MAPT P10636 1/20 0.53
LMNA P02545 3/20 0.51
NR1H4 Q96RI1 1/20 0.51
ALOX15 P16050 1/20 0.51
F12 P00748 1/20 0.51
KDM4E B2RXH2 2/20 0.50
TP53 P04637 1/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 1/20 0.50
HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335299 0.93 ALDH1A1 (0.69) KMT2AALDH1A1MEN1FFAR1SMO
SCHEMBL27817729 0.90 SMO (0.68) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL11852178 0.84 PTPN1 (0.65) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4328096 0.82 CA1 (0.59) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4322719 0.81 KMT2A (0.63) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2021051 0.81 MEN1 (0.57) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL21674204 0.81 MEN1 (0.57) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2997631 0.80 PTPN1 (0.65) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL6521944 0.79 TP53 (0.65) KMT2ANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL437231 0.78 ALDH1A1 (0.87) KMT2AALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7585997-B2 Compounds and compositions for treating dysproliferative diseases, and methods of use thereof CHESTERFORD ENTERPRISES LIMITED (KY) 2009-09-08 US disclosed
EP-1709155-A4 COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF KASHFI KHOSROW (US) 2007-10-31 EP disclosed
EP-1709155-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF Kashfi, Khosrow (US) 2006-10-11 EP disclosed
US-20050182134-A1 Compounds and compositions for treating dysproliferative diseases, and methods of use thereof CONVERSANT INTELLECTUAL PROPERTY MANAGEMENT INC. (CA) 2005-08-18 US disclosed
WO-2005065361-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF KASHFI KHOSROW (US) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182134-A1 Compounds and compositions for treating dysproliferative diseases, and methods of use thereof PYGL, TP53, MKI67 KMT2A 4350/4885ALDH1A1 565/4885NPC1 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.